Full-Time
Field Service Engineer
Updated on 8/1/2026
Bruker Corporation
1,001-5,000 employees
Develops analytical instruments for scientific research
Compensation Overview
€33k - €48.4k/yr
Milan, Metropolitan City of Milan, Italy
Remote
Home-based role with travel up to 70% of working time.
 Hardware Engineering (1) |
|---|
Get referred to Bruker Corporation
See people who can refer or advise you
- A bachelor or master degree in Physics, Chemistry, Electronic Engineering, or life science is required.
- Availability to travel up to 70% of the working time is required.
- A driving license is required.
- Italian and English language proficiency at a minimum B2 level is mandatory.
- Knowledge of Windows/Linux operating systems is required.
- Install, train customers on, maintain, and repair NMR systems in the Adriatic region, including Italy, Slovenia, Croatia, Serbia, Greece, Malta, and Cyprus.
- Maintain successful customer relations by understanding customer needs and problems, proposing solutions, and applying what is needed for excellent customer satisfaction.
- Become familiar with the GxP environment.
- Provide service in the Europe, Middle East and Africa region and worldwide when needed.
- Knowledge of NMR/EPR spectroscopy is an additional asset.
Bruker Corporation provides analytical and diagnostic instruments used in life sciences, materials science, and environmental analysis. Its product lines include technologies such as nuclear magnetic resonance (NMR), mass spectrometry, imaging, and spectroscopy, which help researchers analyze the composition, structure, and properties of samples. These instruments work by measuring physical signals (like magnetic resonance, ion fragmentation patterns, or spectral fingerprints) from samples and translating them into data and insights via specialized software and workflows. Bruker differentiates itself through a long history of NMR expertise since 1960, a broad, integrated portfolio of measurement platforms, and a global footprint that supports researchers from development to routine analysis. Its goal is to empower scientists and industry professionals to advance research and solve real-world problems by providing reliable analytical tools and solutions.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Billerica, Massachusetts
Founded
1960
Get referred to Bruker Corporation
See people who can refer or advise you
Simplify's Take
What believers are saying
- DISQVER targets sepsis, endocarditis, and bloodstream infections with under-24-hour analysis.[1]
- Bruker can cross-sell NGS, AST, hygiene, and molecular diagnostics into hospitals.[1]
- Select acquisition of distressed IP and staff can expand capabilities efficiently.[1]
What critics are saying
- DISQVER remains research use only, delaying diagnostic revenue until registration completes.[1]
- Noscendo's insolvency exposed weak commercialization and hospital budget pressure.[1]
- Bruker faces integration risk from acquired software, IP, and select personnel.[1]
What makes Bruker Corporation unique
- Founded by Günther Laukien in 1960, rooted in NMR innovation.[1][5]
- Broad portfolio spans analytical instruments, diagnostics, microscopy, and semiconductor metrology.[1]
- DISQVER adds metagenomic blood testing to Bruker's infection-diagnostics platform.[1]
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Paid Vacation
Paid Sick Leave
Paid Holidays
Disability Insurance
Life Insurance
Dental Insurance
Flexible Work Hours
Employee Discounts
Growth & Insights and Company News
6 month growth
↑ 14%1 year growth
↑ 14%2 year growth
↑ 14%US life sciences company Bruker has acquired the DISQVER platform and selected assets of insolvent German diagnostics startup Noscendo through a restructuring sale. Financial terms were not disclosed. Duisburg-based Noscendo, founded in 2016, developed a method for identifying pathogens in under 24 hours using next-generation sequencing from cell-free DNA. The technology is used by university hospitals for sepsis diagnostics. Despite raising nearly €40 million in venture capital, commercialisation proceeded slower than expected due to delays in selective contracts and economic pressure on hospitals. A planned financing round with existing investors failed in February 2026, leading to insolvency proceedings in March. Insolvency administrator Sarah Wolf from Anchor Rechtsanwälte said the restructuring preserved the technology's value for creditors and partners. Bruker acquired the patent-protected software, intellectual property rights, and select IT and sales staff in Duisburg. The laboratory in Kusterdingen was partially closed in April.